XML 22 R11.htm IDEA: XBRL DOCUMENT v3.25.1
STOCKHOLDERS' EQUITY
 3 Months Ended
Mar. 31, 2025
Equity [Abstract]  
STOCKHOLDERS' EQUITY STOCKHOLDERS’ EQUITY
Activity in equity during the three month periods ended March 31, 2025 and 2024 was as follows (dollars in thousands):
Common StockAdditional
Paid-In
Capital 		Accumulated
Deficit 		Total
SharesAmount
2025
Balances as of December 31, 20241,035,893 $1 $138,607 $(136,097)$2,511 
Stock-based compensation— — 91 — 91 
Issuance of common stock, net of transaction costs365,319 — 1,066 — 1,066 
Issuance of common stock upon exercise of warrants, net of transaction costs374,718 1 888 — 889 
Net loss— — — (1,665)(1,665)
Balances as of March 31, 20251,775,930 $2 $140,652 $(137,762)$2,892 
2024
Balances as of December 31, 2023514,003 $1 $136,263 $(129,913)$6,351 
Stock-based compensation— — 85 — 85 
Issuance of common stock upon exercise of warrants, net of transaction costs460 — 6 — 6 
Net loss— — — (1,832)(1,832)
Balances as of March 31, 2024514,463 $1 $136,354 $(131,745)$4,610 
In March 2025, we completed a warrant inducement transaction whereby we issued 374,718 shares of common stock pursuant to the exercise of warrants. Certain warrant holders were induced to exercise warrants by reducing the exercise price to the then current market price of our common stock (the “Warrant Inducement”). The original warrants consisted of 251,884 shares issued August 23, 2024 with an exercise price of $4.35 per share and a remaining life of 4.5 years (“Series F-1 Warrants”) and 122,834 shares issued August 23, 2024 with an exercise price of $4.35 per share and a remaining life of 1.0 year (“Series F-2 Warrants”) (collectively, the “Original Warrants”). The Original Warrants were exercised for $2.90 per share for gross proceeds of $1.1 million, before deducting $197,000 of issuance costs.
The difference between the fair value of the warrants immediately prior to modification and immediately after modification was treated as a transaction cost, which is netted against proceeds received, and was $58,000 using the Black-Scholes model based on the following significant inputs:
•For the Series F-1 Warrants: common stock price of $2.38 per share; volatility of 120%; term of 4.5 years; dividend yield of 0%; and risk-free rate of 4.0%; and
•For the Series F-2 Warrants: common stock price of $2.38 per share; volatility of 111%; term of 1.0 year; dividend yield of 0%; and risk-free rate of 4.0%.
In connection with the Warrant Inducement transaction, new short-term warrants to purchase 1,517,608 shares of our common stock were issued, which are discussed in Note 7.
In June 2024, we entered into an at-the-market offering arrangement with a sales agent, pursuant to which we may offer and sell, from time to time at our sole discretion, in transactions that are deemed to be “at the market” offerings under the Securities Act of 1933, as amended (the “Securities Act”), shares of our common stock for aggregate gross proceeds of up to approximately $1.6 million (“ATM Facility”). The offer and sale of shares are made pursuant to a previously filed shelf registration statement on Form S-3 (Registration no. 333-261227), originally filed with the SEC on November 19, 2021 and amended on May 4, 2022, and declared effective by the SEC on May 6, 2022, and the related prospectus supplement related to the offering of shares dated June 20, 2024, and filed with the SEC on such date pursuant to Rule 424(b) under the Securities Act. For additional information, see Note 11, Subsequent Events. During the first quarter of 2025, we have sold 365,319 shares of common stock under this ATM Facility for gross proceeds of $1.2 million, before deducting offering expenses of $159,000. As of March 31, 2025, there are 34,819 shares of common stock reserved for potential issuance under the ATM Facility.
COMMON STOCK WARRANTS
The following table presents the common stock warrant activity:
Issue DateWarrant TypeTerm
Date		Exercise
Price		Balance December 31, 2024IssuedExercisedExpiredBalance March 31, 2025
January 2020Registered Direct OfferingJuly 2025$21,600.00 60———60
January 2020Dealer ManagerJanuary 2025$24,000.00 4——(4)—
March 2020Dealer ManagerMarch 2025$9,015.12 4——(4)—
April 2020Dealer ManagerApril 2025$9,528.00 47———47
April 2020Registered Direct OfferingApril 2025$7,320.00 20———20
October 2020Dealer ManagerApril 2026$5,174.40 34———34
February 2021Private Placement AgreementAugust 2026$5,318.40 540———540
February 2021Dealer ManagerAugust 2026$6,835.40 136———136
March 2021Dealer ManagerMarch 2026$6,000.00 60———60
November 2022Dealer ManagerNovember 2027$525.00 892———892
April 2023Series COctober 2028$194.40 7,142———7,142
April 2023Dealer ManagerApril 2028$262.50 534———534
August 2023Dealer ManagerAugust 2028$108.04 1,222———1,222
November 2023Series DNovember 2028$13.00 151,026———151,026
November 2023Series EMay 2025$13.00 80,998———80,998
November 2023Dealer ManagerNovember 2028$16.25 28,844———28,844
August 2024Series F-1August 2029$4.35 571,318—(251,884)—319,434
August 2024Series F-2February 2026$4.35 439,686—(122,834)—316,852
August 2024Dealer ManagerAugust 2029$5.75 25,275———25,275
August 2025Series GSeptember 2026$2.90 —1,498,872——1,498,872
August 2024Dealer ManagerSeptember 2026$3.625 —18,736——18,736
1,307,8421,517,608(374,718)(8)2,450,724
SharesWeighted
Average
Exercise
Price Per
Share		Weighted
Average
Remaining
Contractual
Term
(years)
Outstanding as of December 31, 20241,307,842 $12.63 3.4
Issued1,517,608 2.91 1.5
Exercised(374,718)2.90 — 
Expired(8)16,507.56 — 
Outstanding as of March 31, 20252,450,724 7.82 1.9
In connection with the Warrant Inducement transaction discussed in Note 6, we issued to those investors warrants to purchase up to 1,498,872 shares of our common stock at an exercise price of $2.90 per share, which will be exercisable for 1.5 years beginning on the effective date of stockholder approval of the issuance of the shares of common stock. We estimated the fair value of these warrants to be $1.5 million using a Black-Scholes model based on the following significant inputs: common stock price of $2.38 per share; volatility of 117%; term of 1.5 years; dividend yield of 0%; and risk-free rate of 4.37%.
In addition, placement agent warrants were issued to purchase up to 18,736 shares of our common stock at an exercise price of $3.625 per share, which will be exercisable for 1.5 years beginning on the effective date of stockholder approval of the issuance of the shares of common stock. We estimated the fair value of these warrants to be $20,000 using a Black-Scholes model based on the following significant inputs: common stock price of $2.38 per share; volatility of 117%; term of 1.5 years; dividend yield of 0%; and risk-free interest rate of 4.37%.